TG Therapeutics (NASDAQ:TGTX) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research note published on Wednesday,Benzinga reports. The firm currently has a $55.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for TG Therapeutics’ FY2025 earnings at $1.26 EPS.

A number of other analysts have also issued reports on the company. The Goldman Sachs Group boosted their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. Finally, TD Cowen started coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Trading Up 1.5 %

Shares of TG Therapeutics stock opened at $30.18 on Wednesday. The business’s fifty day simple moving average is $31.69 and its 200-day simple moving average is $25.63. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics has a 52 week low of $12.84 and a 52 week high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same period last year, the business earned $0.73 EPS. Research analysts predict that TG Therapeutics will post 0.07 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,358 shares of company stock worth $781,497. Corporate insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. State Street Corp raised its stake in TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of TG Therapeutics during the second quarter worth about $36,501,000. Principal Financial Group Inc. lifted its holdings in shares of TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of TG Therapeutics in the 2nd quarter valued at about $10,423,000. Finally, Public Sector Pension Investment Board purchased a new position in TG Therapeutics during the 3rd quarter worth approximately $6,619,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.